Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

TLX vs TRNI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLX Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–2 Matrix Metrics)

TLX Overall Winner 6-Pillar Tally: TLX 5 – 0 TRNI (1 Tie) Matrix Metrics: TLX 7 – 2 TRNI

As of Nov 20, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over TRNI (TRNI) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 37.6/100 (SELL) at $8.37 (N/M Forward P/E, 6.2% operating margin), whereas TRNI carries 44.3/100 (HOLD) at $25.00 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While TRNI currently prints a higher short-term Unified Composite Score (44.3/100 HOLD vs. TLX 37.6/100 SELL), TLX captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (6.2% vs. N/A operating margin) and revenue trajectory (+22.3% vs. N/A YoY).
  • Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.4); meanwhile TRNI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLX vs TRNI
TLX NASDAQ Head-to-Head Winner
Telix Pharmaceuticals Limited American Depositary Shares
Pharmaceutical Preparations
$8.37
-3.9% 1D
Market Cap $3.0B
TTM Revenue $891M
Forward P/E N/M
Beta / 30D Vol 0.91β · 48% Vol
Unified Composite Score
37.6 / 100 SELL
Tech 19.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.6%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $9.21 · SMA50: $10.36
TRNI US Equity
TRNI
Institutional Equity
$25.00
-0.16% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.03β · 3% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 48.0 Fund 51.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.4%) with fading momentum, RSI 44
RSI-14: 43.6 · SMA20: $25.08 · SMA50: $25.05

6-Pillar Scorecard Institutional Category Breakdown (TLX 5 – 0 TRNI)

Columns: Metric · TLX · TRNI
1. Valuation Multiples TLX
Forward P/E N/M N/M
Trailing P/E 87.1x N/M
PEG Ratio N/M N/M
EV / Revenue 3.3x N/M
2. Growth & Scale TLX
Revenue Growth (YoY) +22.3% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $891M N/A
Market Cap $3.0B N/A
3. Profitability & Quality TLX
Gross Margin 47.6% N/A
Operating Margin 6.2% N/A
Net Profit Margin 3.8% N/A
Return on Equity (ROE) 7.4% N/A
4. Balance Sheet & Cash Flow TLX
Cash Generation (TTM) $70M EBITDA N/A
Cash Flow Margin 7.8% EBITDA Mgn N/A
Net Cash / Leverage $1.44 Book/Sh · 7.4% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat TLX
OpEx & R&D Intensity 41.4% of Rev ($369M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLX (7) vs TRNI (2)
Institutional Metric TLX TRNI Criterion Row Edge
Market Capitalization
Scale
$3.0B N/A Larger Scale TLX
Trailing P/E Ratio
Valuation
87.1x N/M Lower Multiple TLX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+22.3% N/A Higher Growth TLX
Operating Margin (TTM)
Profitability
6.2% N/A Higher Margin TLX
Net Profit Margin
Profitability
3.8% N/A Higher Margin TLX
Return on Equity (ROE)
Capital Efficiency
7.4% N/A Higher ROE TLX
52-Week Range Position
Momentum
31% ($6–$13) 25% ($25–$25) Stronger Trend TLX
Beta / 30D Volatility
Risk Regime
0.91β · 48% Vol 0.03β · 3% Vol Lower Realized Risk TRNI
Unified Institutional Score
Composite Signal
37.6 / 100 (SELL) 44.3 / 100 (HOLD) Higher Composite TRNI
Trailing 12M Revenue (USD)
Operating Scale
$891M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$70M EBITDA ($1.44 Book/Sh · 7.4% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TRNI +12.3 pp
TLX: -12.26% · TRNI: +0.04%
3M Horizon TRNI +27.0 pp
TLX: -28.34% · TRNI: -1.34%
6M Horizon TRNI +15.18 pp
TLX: -16.13% · TRNI: -0.95%
1Y Horizon TRNI +15.18 pp
TLX: -16.13% · TRNI: -0.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLX vs TRNI. Trailing 12-month operating profitability (TLX 6.2% vs TRNI N/A) and valuation multiples (TLX N/M vs TRNI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$891M
Gross Margin47.6%
Op. Margin6.2%
ROE / Fwd P/E7.4% · N/M
TRNI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TRNI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TRNI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment 41.4% of Rev ($369M)
90D Engineering Disclosures 0 Published
TRNI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TLX vs TRNI Key Questions & Quantitative Answers

As of Nov 20, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over TRNI (TRNI) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 37.6/100 (SELL) at $8.37 (N/M Forward P/E, 6.2% operating margin), whereas TRNI carries 44.3/100 (HOLD) at $25.00 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While TRNI currently prints a higher short-term Unified Composite Score (44.3/100 HOLD vs. TLX 37.6/100 SELL), TLX captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (6.2% vs. N/A operating margin) and revenue trajectory (+22.3% vs. N/A YoY). Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.4); meanwhile TRNI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLX leads the Growth & Scale pillar: TLX posts +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin), compared with TRNI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, TLX generates $891M in USD-normalized revenue versus N/A for TRNI. In operating R&D and SG&A reinvestment, TLX deploys 41.4% of Rev ($369M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TRNI.

TLX screens cheaper on headline valuation multiples. TLX trades at N/M Forward P/E, 87.1x Trailing P/E, N/M PEG, and 3.3x EV/Revenue (7.8% EBITDA margin), whereas TRNI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLX (7.4% ROE) versus TRNI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.91β · 48% Vol realized risk). By comparison, TRNI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 3% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.